Inovio Pharmaceuticals Inc Market Cap ($105.80 Million)
Market Cap & Net Worth: Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals Inc market cap. Inovio Pharmaceuticals Inc (NASDAQ:INO) has a market capitalization of $105.80 Million ($105.80 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18779 globally and #4363 in its home market, demonstrating a 90.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inovio Pharmaceuticals Inc's stock price $1.66 by its total outstanding shares 68703375 (68.70 Million). Also see Inovio Pharmaceuticals Inc (INO) cash conversion ratio for how efficiently the company converts equity into cash flow.
Inovio Pharmaceuticals Inc Market Cap History (2015–2026)
Inovio Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows change from $5.53 Billion to $114.05 Million (-29.17% CAGR). Check INO share price today for real-time trading data and today's change.
Index Memberships
Inovio Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #515 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1802 of 3165 |
Weight: Inovio Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Inovio Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inovio Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Inovio Pharmaceuticals Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
577.38x
Inovio Pharmaceuticals Inc's market cap is 577.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.53 Billion | $40.57 Million | -$29.19 Million | 136.29x | N/A |
| 2016 | $5.71 Billion | $35.37 Million | -$73.74 Million | 161.46x | N/A |
| 2017 | $3.40 Billion | $42.22 Million | -$88.21 Million | 80.65x | N/A |
| 2018 | $3.30 Billion | $30.48 Million | -$96.97 Million | 108.19x | N/A |
| 2019 | $2.72 Billion | $4.11 Million | -$119.36 Million | 661.65x | N/A |
| 2020 | $7.30 Billion | $7.41 Million | -$166.41 Million | 984.49x | N/A |
| 2021 | $4.11 Billion | $1.77 Million | -$303.66 Million | 2318.04x | N/A |
| 2022 | $1.29 Billion | $10.26 Million | -$279.82 Million | 125.33x | N/A |
| 2023 | $420.46 Million | $832.01K | -$135.12 Million | 505.36x | N/A |
| 2024 | $125.73 Million | $217.76K | -$107.25 Million | 577.38x | N/A |
Competitor Companies of INO by Market Capitalization
Companies near Inovio Pharmaceuticals Inc in the global market cap rankings as of November 5, 2026. Also see Inovio Pharmaceuticals Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Inovio Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Inovio Pharmaceuticals Inc (2015–2026)
Market capitalization of Inovio Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Inovio Pharmaceuticals Inc's market cap moved from $5.53 Billion to $ 114.05 Million, with a yearly change of -29.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $114.05 Million | -4.60% |
| 2025 | $119.54 Million | -4.92% |
| 2024 | $125.73 Million | -70.10% |
| 2023 | $420.46 Million | -67.31% |
| 2022 | $1.29 Billion | -68.74% |
| 2021 | $4.11 Billion | -43.62% |
| 2020 | $7.30 Billion | +168.18% |
| 2019 | $2.72 Billion | -17.50% |
| 2018 | $3.30 Billion | -3.15% |
| 2017 | $3.40 Billion | -40.38% |
| 2016 | $5.71 Billion | +3.27% |
| 2015 | $5.53 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Inovio Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $105.80 Million USD |
| MoneyControl | $105.80 Million USD |
| MarketWatch | $105.80 Million USD |
| marketcap.company | $105.80 Million USD |
| Reuters | $105.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more